Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

Circumstances of FDA's approval of Sarepta's Exondys 51 approval may give BioMarin reason to appeal the complete response for its Duchenne muscular dystrophy treatment drisapersen – but its high-quality data could preclude success.